{"id":657327,"date":"2023-06-27T07:30:01","date_gmt":"2023-06-27T07:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=657327"},"modified":"2023-06-27T07:30:01","modified_gmt":"2023-06-27T07:30:01","slug":"chemotherapyinduced-peripheral-neuropathy-cipn-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-algotx-ananda-hemp-annji-aptinyx","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-peripheral-neuropathy-cipn-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-algotx-ananda-hemp-annji-aptinyx_657327.html","title":{"rendered":"Chemotherapy-induced Peripheral Neuropathy (CIPN) Market to Exhibit Moderate Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AlgoTx, Ananda Hemp, AnnJi, Aptinyx"},"content":{"rendered":"
\n
\"Chemotherapy-induced<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Chemotherapy-induced Peripheral Neuropathy (CIPN) Market size in the 7MM was ~USD 1,500 million in 2022, which is expected to grow by 2032. As per DelveInsight, the Chemotherapy-induced Peripheral Neuropathy Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and the expected entry of emerging therapies in the market.<\/div>\n

DelveInsight’s “Chemotherapy-induced Peripheral Neuropathy (CIPN) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy-induced Peripheral Neuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Chemotherapy-induced Peripheral Neuropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chemotherapy-induced Peripheral Neuropathy treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Chemotherapy-induced Peripheral Neuropathy (CIPN): An Overview<\/strong><\/p>\n

CIPN is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.<\/p>\n

CIPN presents clinically as deficits in sensory, motor, and sometimes autonomic function. Sensory disturbances range from a mild tingling sensation to spontaneous burning pain and hypersensitivity to stimuli. These symptoms often affect both hands and feet and may spread into a ‘glove\/stocking’ distribution. Symptoms are usually symmetrical distally but may be more severe unilaterally. Although dependent on the specific agent, the feet are often affected first<\/p>\n

Chemotherapy-induced Peripheral Neuropathy (CIPN) Market Key Facts<\/strong><\/p>\n